The FDA has approved Apidra SoloSTAR (insulin glulisine[rDNA origin] injection, from sanofi-aventis), a prefilled disposable pencontaining Apidra.  Apidra SoloSTAR makes administration of insulin moreconvenient for patients with insulin regimens that require rapid-acting Apidra. It is expected to be available in pharmacies thisyear.

Apidra is indicated to improve glycemic control inadults and children ≥4 years of age with type 1 diabetes or adults with type 2 diabetes.

For more information call (800) 633-1610 or visit www.Apidra.com.